Long-Term Returns of Dan Loeb’s 5 Activist Targets

2. Ventyx Biosciences, Inc. (NASDAQ:VTYX) 

Stock Return: 66%
Activist Investment: 2022

Ventyx Biosciences, Inc. (NASDAQ:VTYX) is a clinical-stage biopharmaceutical company that develops small-molecule product candidates for various inflammatory diseases. In December of 2022, Third Point took a position on the company as Loeb remained optimistic about its pipeline and potential to create medicine for patients with autoimmune diseases.

Given that the hedge fund purchased the shares at an average price of about $18.95, the value of its stake has increased by about 66%.

Follow Ventyx Biosciences Inc.